MedTrace Logo

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

NCT06441890 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-07-14

No results posted yet for this study

Summary

Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care

Conditions

Interventions

DRUG

Paclitaxel

80mg/m2 IV D1, 8, 15

DRUG

Nab-paclitaxel

125mg/m2 IV D1, 8, 15

DRUG

Docetaxel

75mg/m2 IV D1

DRUG

Trastuzumab

8mg/kg loading, then 6mg/kg IV/SQ D1

DRUG

Pertuzumab

840 mg loading, then 420mg IV/SQ D1

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-05
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06441890 on ClinicalTrials.gov